Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308977424> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W4308977424 endingPage "vii64" @default.
- W4308977424 startingPage "vii64" @default.
- W4308977424 abstract "Abstract BACKGROUND Newly diagnosed glioblastoma (nGBM) has a dismal prognosis with survival of 15-18 months. Tumor associated “survivin” protein is expressed in >95% of nGBM and is targetable with the use of SurVaxM, shown to be effective at generating cytotoxic T lymphocytes. METHODS nGBM patients are being enrolled in this randomized placebo-controlled trial phase II study. Eligibility Criteria includes age ≥ 18, KPS ≥ 70, IHC confirmed survivin-expression, and residual contrast enhancement of ≤1 cm3 by MRI, within 72 hours of surgical resection. Patients are randomized 3:2 into two arms A:B to treatment with SurVaxM in emulsion with Montanide plus sargramostim (local injection) and standard-of-care TMZ (Arm A), or placebo (saline in emulsion with Montanide) plus saline (local injection) and standard-of-care TMZ (Arm B). There are three active treatment phases in the study with vaccine priming (VP) phase; adjuvant TMZ phase; and Vaccine Maintenance (VM) phase. A total of four (4) priming doses of SurVaxM in Montanide plus sargramostim (“SurVaxM/sargramostim”) or placebo in Montanide/saline (“Placebo/Placebo”) will be administered every two weeks ( ± 3 days) during the priming phase, with subsequent dosing every 8 weeks ( ± 1 week) during the vaccine maintenance phase. After priming doses, SurVaxM/sargramostim or Placebo/Placebo will be administered every 8 weeks ( ± 1 week) until tumor progression or for a maximum of 24 months. The total sample size is of 265 patients, with 159 patients in the SurVaxM arm and 106 patients in the control arm. The primary objective is to determine the overall survival (OS), and the secondary objectives include progression-free survival (PFS), OS at pre-specified time points (OS-15, OS-18 and OS-24), PFS at pre-specified time points (PFS-3, PFS-6 and PFS-12) and evaluation of toxicities. Study duration is expected at 36 months, with enrollment ongoing at several centers and planned for total of 20 participating centers." @default.
- W4308977424 created "2022-11-20" @default.
- W4308977424 creator A5012095208 @default.
- W4308977424 creator A5012877310 @default.
- W4308977424 creator A5018341423 @default.
- W4308977424 creator A5025984713 @default.
- W4308977424 creator A5035416012 @default.
- W4308977424 creator A5036134478 @default.
- W4308977424 creator A5036910737 @default.
- W4308977424 creator A5038295657 @default.
- W4308977424 creator A5045773131 @default.
- W4308977424 creator A5053202206 @default.
- W4308977424 creator A5054741163 @default.
- W4308977424 creator A5056933499 @default.
- W4308977424 creator A5059965175 @default.
- W4308977424 creator A5063612627 @default.
- W4308977424 creator A5067646281 @default.
- W4308977424 creator A5075490964 @default.
- W4308977424 creator A5083922162 @default.
- W4308977424 creator A5090823835 @default.
- W4308977424 date "2022-11-01" @default.
- W4308977424 modified "2023-10-14" @default.
- W4308977424 title "CTIM-20. PROSPECTIVE RANDOMIZED PHASE II PLACEBO-CONTROLLED TRIAL OF SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA (SURVIVE)" @default.
- W4308977424 doi "https://doi.org/10.1093/neuonc/noac209.252" @default.
- W4308977424 hasPublicationYear "2022" @default.
- W4308977424 type Work @default.
- W4308977424 citedByCount "0" @default.
- W4308977424 crossrefType "journal-article" @default.
- W4308977424 hasAuthorship W4308977424A5012095208 @default.
- W4308977424 hasAuthorship W4308977424A5012877310 @default.
- W4308977424 hasAuthorship W4308977424A5018341423 @default.
- W4308977424 hasAuthorship W4308977424A5025984713 @default.
- W4308977424 hasAuthorship W4308977424A5035416012 @default.
- W4308977424 hasAuthorship W4308977424A5036134478 @default.
- W4308977424 hasAuthorship W4308977424A5036910737 @default.
- W4308977424 hasAuthorship W4308977424A5038295657 @default.
- W4308977424 hasAuthorship W4308977424A5045773131 @default.
- W4308977424 hasAuthorship W4308977424A5053202206 @default.
- W4308977424 hasAuthorship W4308977424A5054741163 @default.
- W4308977424 hasAuthorship W4308977424A5056933499 @default.
- W4308977424 hasAuthorship W4308977424A5059965175 @default.
- W4308977424 hasAuthorship W4308977424A5063612627 @default.
- W4308977424 hasAuthorship W4308977424A5067646281 @default.
- W4308977424 hasAuthorship W4308977424A5075490964 @default.
- W4308977424 hasAuthorship W4308977424A5083922162 @default.
- W4308977424 hasAuthorship W4308977424A5090823835 @default.
- W4308977424 hasBestOaLocation W43089774241 @default.
- W4308977424 hasConcept C121608353 @default.
- W4308977424 hasConcept C126322002 @default.
- W4308977424 hasConcept C141071460 @default.
- W4308977424 hasConcept C142724271 @default.
- W4308977424 hasConcept C143998085 @default.
- W4308977424 hasConcept C168563851 @default.
- W4308977424 hasConcept C204243189 @default.
- W4308977424 hasConcept C204787440 @default.
- W4308977424 hasConcept C27081682 @default.
- W4308977424 hasConcept C2775975398 @default.
- W4308977424 hasConcept C2776694085 @default.
- W4308977424 hasConcept C2777389519 @default.
- W4308977424 hasConcept C2777397205 @default.
- W4308977424 hasConcept C2777863537 @default.
- W4308977424 hasConcept C71924100 @default.
- W4308977424 hasConceptScore W4308977424C121608353 @default.
- W4308977424 hasConceptScore W4308977424C126322002 @default.
- W4308977424 hasConceptScore W4308977424C141071460 @default.
- W4308977424 hasConceptScore W4308977424C142724271 @default.
- W4308977424 hasConceptScore W4308977424C143998085 @default.
- W4308977424 hasConceptScore W4308977424C168563851 @default.
- W4308977424 hasConceptScore W4308977424C204243189 @default.
- W4308977424 hasConceptScore W4308977424C204787440 @default.
- W4308977424 hasConceptScore W4308977424C27081682 @default.
- W4308977424 hasConceptScore W4308977424C2775975398 @default.
- W4308977424 hasConceptScore W4308977424C2776694085 @default.
- W4308977424 hasConceptScore W4308977424C2777389519 @default.
- W4308977424 hasConceptScore W4308977424C2777397205 @default.
- W4308977424 hasConceptScore W4308977424C2777863537 @default.
- W4308977424 hasConceptScore W4308977424C71924100 @default.
- W4308977424 hasIssue "Supplement_7" @default.
- W4308977424 hasLocation W43089774241 @default.
- W4308977424 hasOpenAccess W4308977424 @default.
- W4308977424 hasPrimaryLocation W43089774241 @default.
- W4308977424 hasRelatedWork W2002120878 @default.
- W4308977424 hasRelatedWork W2003938723 @default.
- W4308977424 hasRelatedWork W2039865683 @default.
- W4308977424 hasRelatedWork W2047967234 @default.
- W4308977424 hasRelatedWork W2118496982 @default.
- W4308977424 hasRelatedWork W2439875401 @default.
- W4308977424 hasRelatedWork W4200435011 @default.
- W4308977424 hasRelatedWork W4225117058 @default.
- W4308977424 hasRelatedWork W4238867864 @default.
- W4308977424 hasRelatedWork W2525756941 @default.
- W4308977424 hasVolume "24" @default.
- W4308977424 isParatext "false" @default.
- W4308977424 isRetracted "false" @default.
- W4308977424 workType "article" @default.